Scholar Rock at Jefferies: Leadership Changes and Drug Launch Plans

Scholar Rock (SRRK) presented at the Jefferies Global Healthcare Conference 2025, focusing on the anticipated FDA approval of epitogromab for SMA, with a PDUFA date of September 22nd, and a potential European launch in mid-2026 following a recent filing; the company highlighted its new leadership team and their extensive experience in rare disease commercialization, while acknowledging the competitive landscape and reimbursement challenges for SMA therapies. While the BLA review for epitogromab is progressing positively with no AdCom indication, the company is also cautiously evaluating its obesity program, influenced by recent data on lean mass loss in obesity treatments, but remains primarily focused on its SMA program and pipeline of neuromuscular disorder therapeutics.

Analysis

Scholar Rock (NASDAQ:SRRK) detailed its strategic priorities at the Jefferies Global Healthcare Conference, centering on the upcoming PDUFA date of September 22nd for its Spinal Muscular Atrophy (SMA) drug, epitogromab. The company's new leadership, including CEO David Hallal (former Chairman with experience at Amgen, Alexion, Biogen) and President of R&D Akshay Vaishna (formerly Alnylam), brings substantial rare disease commercialization expertise, aiming to navigate epitogromab's launch amidst a competitive SMA market and existing reimbursement complexities, though the overall reimbursement landscape for SMA drugs is considered favorable. The Biologics License Application (BLA) review for epitogromab is reportedly progressing positively with the FDA, with no current indication of an Advisory Committee (AdCom) meeting, and Scholar Rock is optimistic about achieving a broad label covering various patient ages and conditions. A European launch is anticipated in mid-2026. Concurrently, Scholar Rock is cautiously evaluating its obesity program, with data from the EMBRAICE study (epitogromab with tirzepatide) expected later in June. This evaluation is influenced by recent findings from Regeneron's COURAGE trial, which, while validating myostatin inhibition for lean mass preservation (around 50%), also highlighted potential safety concerns with combination or high-dose anti-myostatin antibodies, a point Scholar Rock believes its distinct approach might address favorably. Despite this, the company underscored its primary commitment to rare neuromuscular disorders, particularly SMA, and is carefully considering the clinical and regulatory pathways for its obesity asset to avoid potential development 'traps'.

Key Decisions for Investors

• Investors should monitor the upcoming PDUFA date of September 22nd for epitogromab as a key near-term catalyst, given the positive FDA interactions reported.
• Consider the extensive rare disease experience of the new leadership team as a significant factor in potentially de-risking the commercial launch and strategic execution for epitogromab, though a gradual market uptake is anticipated.
• Evaluate the EMBRAICE study data for the obesity program, expected in June, with an understanding that the company is prioritizing its SMA franchise and approaching the obesity market cautiously, potentially limiting near-term upside from this secondary program but focusing resources effectively.
• Assess the company's ability to secure a broad label for epitogromab, which will be crucial for market penetration against established SMA therapies, and watch for further updates on the European regulatory timeline.